Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039708 | PMC |
| http://dx.doi.org/10.1038/s41386-023-01768-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to: Measles Foci Reduction Neutralization Test (FRNT).
Methods Mol Biol
January 2024
National Reference Center Measles, Mumps, Rubella, Robert Koch-Institute, Berlin, Germany.
Haemotoxicity of snakes: a review of pathogenesis, clinical manifestations, novel diagnostics and challenges in management.
Trans R Soc Trop Med Hyg
January 2025
Department of Clinical Medicine, Faculty of Medicine, University of Colombo, P.O. 00800, Sri Lanka.
Haemotoxicity is the most common complication of systemic envenoming following snakebite, leading to diverse clinical syndromes ranging from haemorrhagic to prothrombotic manifestations. Key haematological abnormalities include platelet dysfunction, venom-induced consumption coagulopathy, anticoagulant coagulopathy and organ-threatening thrombotic microangiopathy. Diagnostic methods include the bedside whole blood clotting test, laboratory coagulation screening and other advanced methods such as thromboelastogram and clot strength analysis.
View Article and Find Full Text PDFPredicting RNA Structure and Dynamics with Deep Learning and Solution Scattering.
Biophys J
December 2024
School of Computer Science and Engineering, The Hebrew University of Jerusalem, Israel. Electronic address:
Advanced deep learning and statistical methods can predict structural models for RNA molecules. However, RNAs are flexible, and it remains difficult to describe their macromolecular conformations in solutions where varying conditions can induce conformational changes. Small-angle X-ray scattering (SAXS) in solution is an efficient technique to validate structural predictions by comparing the experimental SAXS profile with those calculated from predicted structures.
View Article and Find Full Text PDFReplacing serum with dried blood microsampling for pharmacokinetics, viral neutralisation and immunogenicity bioanalysis supporting future paediatric development of RSM01, a candidate respiratory syncytial virus neutralising monoclonal antibody.
BMC Infect Dis
December 2024
Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
Background: Virus neutralising antibodies in serum are considered key correlates of protection for vaccines and monoclonal antibodies against respiratory syncytial virus (RSV). RSM01 is a novel, highly-potent, half-life-extended and fully-human monoclonal antibody candidate targeting the RSV prefusion F protein. Currently in Phase 1 development, RSM01 is primarily being developed to potentially provide an effective and affordable RSV prevention strategy in low- and middle-income countries.
View Article and Find Full Text PDFThe anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood .
Res Pract Thromb Haemost
November 2024
Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Background: The development of anticoagulants that provide antithrombotic efficacy without a concomitant bleeding risk remains an unmet clinical need in thrombosis. Although direct oral anticoagulants (DOACs) have a reduced incidence of major bleeding compared with warfarin, they still carry a bleeding risk, resulting in a suboptimal therapeutic index. Epidemiologic data suggest that inhibiting activated factor XI (FXIa) may offer an improved safety profile with respect to bleeding risk compared with current-generation DOACs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!